Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma.
Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma.
Adv Urol. 2018;2018:7978958
Authors: Hu B, Daneshmand S
Abstract
Reducing the long-term morbidity in testicular cancer survivors represents a major area of interest. External beam radiation therapy and systemic chemotherapy are established treatments for seminoma; however, they are associated with late toxicities such as cardiovascular disease, insulin resistance, and secondary malignancy. Retroperitoneal lymph node dissection (RPLND) is a standard treatment for nonseminomatous germ cell tumors (NSGCT) that has minimal long-term morbidity. Given the efficacy of RPLND in management of NSGCT, interest has developed in this surgery as a front-line treatment for seminoma with isolated lymph node metastasis to the retroperitoneum. Four retrospective studies have shown promising results when surgery is performed for seminomas with low-volume retroperitoneal metastases. To better determine if RPLND can be recommended as a primary treatment option, two prospective clinical trials (SEMS and PRIMETEST) are underway. This review will examine the literature, discuss the benefits/limitations of RPLND, and compare the methodologies of the two ongoing clinical trials.
PMID: 29487620 [PubMed]
Source: Advances in Urology - Category: Urology & Nephrology Tags: Adv Urol Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | External Beam Therapy | Germ Cell Tumors | Heart | Insulin | Radiation Therapy | Seminoma | Study | Testicular Cancer | Toxicology | Urology & Nephrology